Cell injection therapy for systemic sclerosis
Part of Skin clinical trials.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a confirmed diagnosis of systemic sclerosis (diffuse type) for 5 years or less.
- You should have a skin hardening score between 10 and 30 (measured by a doctor).
- You must have tried at least two previous treatments for your condition, like steroids or immune-suppressing drugs.
- You cannot have severe lung problems, recent heart issues, or certain other serious health conditions.
- You must not have had stem cell treatment before or be pregnant or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 trial tests a new cell therapy (89Zr-Oxine-RY_SW01) for people with diffuse scleroderma who have not responded well to at least two prior treatments. The goal is to see if this treatment is safe and could help control the disease.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
This study tests a new type of cell therapy (CAR T-cells) to see if it works better than current treatments for active systemic sclerosis. It is designed for people whose lung disease is not well controlled by standard therapy.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
This study looks at skin cells and immune cells in people with systemic sclerosis to better understand what drives the disease. Your participation may help researchers learn how the immune system and skin support cells change over time.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.